Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h00 HE
|
Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
11 mars 2024 08h00 HE
|
Avenue Therapeutics
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07 mars 2024 16h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
05 mars 2024 07h00 HE
|
Praxis Precision Medicines, Inc.
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
22 févr. 2024 08h30 HE
|
Avenue Therapeutics
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 févr. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive Therapeutics, Takeda, Ovid Therapeutics, Eisai, Biohaven Pharmaceuticals, UCB Pharma
08 févr. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive...
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08 févr. 2024 08h00 HE
|
Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders
Epilepsy Therapeutics market is projected to grow at a CAGR of 8.1% by 2034: Visiongain
02 févr. 2024 04h00 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Epilepsy Therapeutics Market Report 2024-2034: Forecasts by Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), by...
APAC Epilepsy Therapeutic Market Poised for Growth, Set to Expand by USD 449.35 Mn through 2023-2028
31 janv. 2024 11h13 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Epilepsy Therapeutic Market in APAC 2024-2028" report has been added to ResearchAndMarkets.com's offering. The epilepsy therapeutic market in the...